emerg
price month
everyth sunni san diego continu
commerci pipelin execut
initi coverag outperform rate
tp among coverag neurocrin top pick smid cap
strong revenu growth profil compound-annual-growth-rate
develop
commerci treatment neurolog diseas includ tardiv dyskinesia
td parkinson diseas pd congenit adren hyperplasia think
ingrezza best-in-class treatment td expect like drive
revenu earn growth next year
best-in-class td blockbust
potenti posit on-going launch ingrezza forecast
potenti sale earli ahead consensu
vari pipelin favor risk/reward neurocrin pipelin
asset stage develop pre-clin phase like
option asset note like fda approv opicapon
pivot studi begin accord compani
updat recent ink gene-therapi partnership
orilissa could market leader endometriosi uterin
fibroid market believ neurocrin could receiv meaning
royalti revenu next year
valuat risk valu share use sum-of-the-part sotp
dcf analysi assum wacc tvgr result tp
risk clinical/development pipelin product
fda/ema approv product commerci ingrezza orilissa
sell well predict price neurocrin abl achiev price
assumpt market risk biotech volatil sector
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
inc commercial-stag
biopharmaceut compani discov develop intend
commerci drug treatment neurolog endocrin
relat diseas disord
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base fda approv
elagolix uterin fibroid opicapon parkinson diseas
also assum posit top-line data phase
congenit adren hyperplasia posit data gene therapi
asset vy-aadc voyag transact
furthermor assum better expect growth ingrezza
orilissa endometriosi
grey sky valuat assum fda approv
elagolix uterin fibroid opicapon parkinson diseas
assum neg top-line phase congenit
adren hyperplasia grey sky also assum lower expect
revenu ingrezza orilissa endometriosi
 close
tabl content
guidanc consensu expect
ingrezza tardiv dyskinesia key revenu earn driver
orilissa endometriosi second commerci asset royalti opportun
elagolix uterin fibroid increment opportun like
opicapon parkinson diseas tuck acquisit modest revenu
congenit adren hyperplasia posit phase need clariti
fda path
collabor voyag therapeut neurolog focus gene therapi
parkinson friedreich ataxia
cs peer relationship neurocrin
initi coverag outperform rate
tp commercial-stag mid-cap biotechnolog compani
focus develop commerci therapeut treat central
nervou system endocrin disord compani main commerci driver
ingrezza valbenazin approv treatment tardiv dyskinesia td/involuntari
movement disord estim could gener revenu
main commerci asset orilissa elagolix market partner
orilissa current approv treat endometriosi women health condit
potenti fda approv treat uterin fibroid noncancer growth uteru
neurocrin receiv tier royalti market partner net
sale estim overal posit neurocrin think
ingrezza franchis like perform better consensu expect given
superior profil teva competit product high unmet need td also expect
addit share upsid driven orilissa late-stag pipelin notabl opicapon
believ neurocrin repres best world
smid-cap biotechcommerci revenu innov pipelin ex-pipelin
project revenu grow compound-annual-growth-rate pleas see industri report
detail larg cap biotech sector
rate neurocrin share outperform tp three main reason
revenu upsid ingrezza franchis td strong pipelin
favor risk/reward asset stage develop financi
flexibl invest busi cash/ invest
valuat risk price target per share base sum-of-the-part
dcf analysi assum discount rate fulli dilut share tax
rate wacc ahead bloomberg wacc howev believ
discount rate reflect risk associ research develop
focus biotechnolog compani earli stage commerci first approv
asset assign termin growth free cash flow assum neurocrin small
molecul asset retain signific valu beyond patent expir commerci
exclus yet believ compani on-going invest
success replac revenu long-term downsid risk
includ clinic development pipelin asset success clinic trial
regulatori fda ema approv delay approv key asset
opicapon orilissa uterin fibroid commerci ingrezza orilissa meet
consensu expect price neurocrin unabl command specialti price
ingrezza put revenu estim risk broader market risk biotech remain
violat sector detail page
ingrezza core share valuat sale asset like drive
revenu earn growth near-term think ingrezza better
competit product name teva austedo due advantag dose schedul lack
titrat superior overal safeti profil neurocrin also benefit exclus
revenu ingrezza asset wholli own even recent disclosur
express script own exclud ingrezza nation formulari
think drug continu outperform formulari impact cover live
estim neurocrin repres actual coverag specif plan
manag express script regard orilissa/elagolix respons
commerci pay royalti estim neurocrin current
approv endometriosi indic potenti approv uterin fibroid indic
potenti fda action date expect asset support long-term
revenu earn growth also gener suffici cash flow allow neurocrin
reinvest busi believ invest pipelin remain prioriti
neurocrin manag outsid ingrezza commerci execut
neurocrin base busi protect late earli increment
valu expect late-st pipelin strong durabl franchis due long
patent life extend brand price exclus orilissa patent expir
like extens ingrezza patent expir
extens forecast increment share valu follow like approv launch
orilissa uf overal think current valuat share underestim
market penetr potenti best-in-class profil ingrezza td orilissa
potenti second-lin therapi treatment choic em key short-term
catalyst compani parkinson diseas pd asset opicapon also like
risk/reward gene-therapi program next gener inhibitor
ingrezza emerg leader tardiv dyskinesia td see ingrezza
main driver growth valu exclud unalloc cost best-in-class
therapi td peak sale estim think neurocrin
ingrezza best posit domin player td market despit
competit teva austedo notabl ingrezza daili dose without need
initi titrat import differenti expect could drive physician usag
patient complianc addit effort neurocrin gain greater market share
includ increas sale forc past year improv diagnosi rate via
physician educ grow prescript given better profil increas
commerci focu believ neurocrin captur major address
td market us
orilissa opportun high unmet need endometriosi uterin fibroid due
larg unmet medic need expect orilissa like first choic therapi
conserv treatment nsaid and/or oral contracept patient em
believ drug potenti second-lin treatment choic due oral
dose option avoid hormon add-back therapi unlik competitor myovant
relugolix immedi drug effect without hormon surg project peak end-
user sale endometriosi peak royalti revenu
repres dcf analysi estim label expans
uterin fibroid could result addit royalti revenu
opicapon potenti best-in-class levodopa extend parkinson diseas
believ larg pd market provid ampl opportun neurocrin potenti make
inroad levodopa extend market improv efficaci toler side effect
dose conveni differenti could drive prefer
competitor comt inhibitor space view believ upsid like depend
commerci market success compani increas market
penetr near term catalyst includ compani expect nda file
project commerci launch
recent ink deal add gene therapi platform
pipelin clinic develop earli ascrib direct valu dcf
analysi like expans gene therapi area
innov highlight companion piec biotechnolog industri
launch within compani core neurosci compet
earli get definit clinic data program pd-focus phase
begin enrol accord compani friedreich ataxia program
still pre-clin develop think program like contribut
long-term revenu base compani
near-term outlook near-term expect share trade continu
commerci execut ingrezza orilissa also see addit upsid
pipelin updat addit detail program potenti regard
gene-therapi collabor voyag could also help support stock
balanc could also get addit inform new
inhibitor novel compound current phase develop
success execut near term catalyst compani expect nda file
opicapon pd elagolix uf could also de-risk later-stag pipelin set
nearer-term revenu base diversif
long-term outlook long-term remain posit neurocrin compani
grow commerci busi diversifi pipelin asset stage
develop see continu consensu perform ingrezza beyond
given better clinic profil believ strong
commerci execut orilissa continu make inroad em market
potenti uf market view expect medium-term pipelin success add
addit upsid share
 outlook think compani could smaller deal
voyag bial cash/short-term invest believ
neurocrin view attract target due grow commerci busi
addit vari pipelin line premium achiev similar asset
mid-cap biotech space ytd believ premium current
trade level could achiev would premium dcf valuat
credit suiss view neurocrin rel peer look neurocrin
profil vs smid-cap large-cap peer note three area differenti
think base-busi like continu grow similar profil
large-cap gilead think high valu
pipelin could gener share upsid near-term neurocrin could
acquir posit strength use current cash balanc engag
busi develop bial voyag
guidanc consensu expect
provid
provid
provid
provid
provid
credit suiss estim factset modifi guidanc includ oper expens due voyag
transact part expens includ in-process expens
ahead revenu ahead consensu expect revenu
primarili driven better expect forecast ingrezza think
asset continu beat expect even year launch potenti
expens guidanc fulli updat reflect voyag offici sg
expens guidanc includ expens associ
voyag transact call compani indic could
addit opex transact factor deriv new expens
guidanc lower end ahead
consensu expect know street includ one-tim charg
expens given higher consensu expens ep
consensu
ingrezza tardiv dyskinesia
neurocrin superior commerci execut differenti
term upsid strong share
acquisit addit market larg unmet need long patent
life competitor provid clear de-risk trajectori
provid
commerci strategi increas physician awar
diagnosi rate via increas sale forc may provid meaning
inroad td market inher difficulti exist chang
physician behavior prescrib habit addit total
address market could decreas next decad first
gener antipsychot less prescrib payer restrict
hamper growth usag product
believ ingrezza continu revenu growth driver neurocrin compani work increas penetr td
market estim sale clinic profil superior competit product austedogiven simplifi
dose titrat believ better safeti profil believ consensu estim conserv like
easi compani beat near- long-term note even modest increas market penetr neurocrin
commerci effort could provid addit upsid number think recent express script updat much
impact sale nation formulari impact cover live
ii orilissa endometriosi uterin fibroid
orilissa could potenti second-lin treatment choic
similar efficaci greater
conveni fewer side effect first-to-market posit
provid addit tailwind relugolix myovant linzagolix
obseva move closer potenti commerci also
posit prospect uf given abil dose orilissa
without add back therapi
increas competit relugolix linzagolix could
significantli erod futur sale due undifferenti therapi
gnrh antagonist market orilissa could lose market
share gnrh agonist similar efficaci greater
experi familiar physician orilissa like also
face headwind uf indic potenti competit
orilissa differenti gnrh agonist class leuprolid oral dose option avoid hormon add-back therapi
immedi drug effect without hormon surg import driver believ could push gnrh antagonist ahead
gnrh agonist agre efficaci data elagolix relugolix linzagolix rel similar clear favorit
point phase trial relugolix linzagolix on-going could produc differenti factor feel unlik base prior
data feel market larg enough three player clinic adopt like base superior market formulari
adopt drive brand prefer across indic royalti could contribut revenu earli
pipelin opicapon parkinson diseas voyag gene therapi collabor
opicapon could therapi choic levodopa extend
parkinson diseas drug proven efficaci toler side
effect conveni dose
drug class
competitor regard pipelin earli stage develop
could provid addit upsid market
signific unmet need also see addit upsid
earlier-stag pipelin current well reflect current
long-term use opicapon could prove unsaf similar
tolcapon smaller expect uptak could occur due
ineffect commerci market neurocrin
signific resourc educ physician patient would
competit space multipl
earli stage minim
penetr
feel opicapon potenti best-in-class comt inhibitor meaning differenti competitor
class larg potenti market opicapon somewhat protect compar therapeut target sinc depend co-
administr levodopath effect therapi pd potenti short-term catalyst includ nda file expect
may result fda approv eventu launch posit phase data program give us confid await
detail plan meet fda path forward collabor voyag could also gener share upsid
addit detail data program releas
compani data credit suiss neurocrin receiv royalti end-us sale model vy-aadc phase asset data provid
figur neurocrin stock price index vs xbi/ibb etf
figur catalyst next month
fda meet adult pivot studi
nda approv commerci launch
price target per share base sum-of-the-part dcf analysi
figur assum discount rate fulli dilut share
tax rate wacc ahead bloomberg wacc howev
believ discount rate reflect risk associ research
develop focus biotechnolog compani earli stage commerci
first approv asset assign termin growth free cash flow assum
neurocrin small molecul asset retain signific valu beyond patent
expir commerci exclus yet believ compani on-going
invest success replac revenu long-
base sotp dcf primarili driven valuat sale ingrezza td
valu opicapon risk adjust royalti
orilissa endometriosi valu po royalti uterin
fibroid indic risk adjust valu program
valu risk adjust combin unalloc corpor
expens net cash sotp dcf valu neurocrin
dcf calcul project share price repres approxim
premium recent close price valuat assumpt
repres middle-ground two approach evalu busi one
view neurocrin compani focus commerci approv asset impli
lower inher risk futur cash flow higher rate termin declin
development-focus organ bear higher degre risk better abl
replenish revenu lost patent expiri sensit analysi impli tight band
valuat two perspect figur
increas /decreas wc
dilut share current price
probabl success pipelin asset
standard probabl success po assumpt phase asset
phase asset phase asset asset nda/bla stage
adjust base program specif histor probabl success specif
diseas categori regard neurocrin pipelin attribut higher po
due posit interim phase data
dcf sensit analys includ sensit analys help support
valuat look differ wacc tvgr termin valu growth rate figur
assum neg flat growth tv still see
dcf valuat higher current share price
figur dcf sensit wacc tvgr varianc price per share
assum better
valuat blue sky scenario assum fda approv
elagolix uterin fibroid opicapon parkinson diseas also assum posit
top-line data phase congenit adren hyperplasia posit data
gene therapi asset vy-aadc voyag transact
ingrezza orilissa
endometriosi key differ base-cas valuat
valuat inclus pipelin credit includ gene
therapi voyag collabor
grey valuat grey sky scenario assum fda approv
elagolix uterin fibroid opicapon parkinson diseas assum neg
top-line phase congenit adren hyperplasia grey sky also assum
lower expect revenu ingrezza orilissa endometriosi
expect growth
clinic development risk mani neurocrin pipelin asset
earli mid-stag clinic develop sever signific risk exist
complet clinic trial includ limit trial enrol delay
efficaci safeti concern poorli design studi inadequ
endpoint insuffici power
regulatori risk neurocrin multipl regulatori submiss expect
next sever year nda file expect opicapon
elagolix uf fda may approv regulatori file potenti
requir costli re-trial discontinu program altogeth fda could requir
potenti confirmatori trial costli time-consum regulatori delay
reject neg impact valu neurocrin share
commerci risk new entrant marketplac could add competit
pressur marketplac exist competitor may produc drug prove
efficaci and/or safer factor lead lower
adopt rate market drug particularli ingrezza could significantli affect
price risk conserv estim pipelin drug price base
compani report transcript feedback signific chang estim
price compar actual price could consider impact revenu forecast
valu neurocrin share drug price current key topic
polit debat ingrezza price could impact polici chang
market risk histor volatil sector unpredict
market forc exist could disrupt equilibrium investor may
bearish biotechnolog potenti drug price legisl may
choos put capit work sector clariti provid
ingrezza tardiv dyskinesia key revenu
earn driver neurocrin
revenu driver neurocrin ingrezza td follow fda approv april
ingrezza treatment tardiv dyskinesia td key revenu long-
term valu driver neurocrin ingrezza vesicular monoamin transport
inhibitor approv link pi use treat movement disord tdwhich side-
effect prolong use antipsychot use bipolar schizophrenia
depress teva austedo inhibitor also approv treat td although
dose regimen black box warn limit use indic much
upsid share root commerci ingrezza
compani sold ingrezza total prescript believ
consensu expect reason inde beatabl histor sale
consist beaten consensu sinc launch figur given superior profil
drug high unmet need td rel low penetr td market see
figur estim vs consensu
contribut sale compar despit season
payer challeng neurocrin cite headwind includ patient health plan chang
medic recertif gross-to-net discount variat larger gross-to-net
discount expect medicar part coverag gap donut hole
although discount lower neurocrin estim expect
net revenu per script benefit move fewer headwind
coverag gap ingrezza continu growth highlight franchis resili expect
stronger growth remaind season dynam settl
formulari chang meaning express script formulari exclus
impact franchis express script announc april exclud ingrezza
nation prefer formulari believ event season formulari
chang like materi affect futur sale neurocrin state
script exclus impact ingrezza sale season formulari chang
meaning chang sale furthermor ingrezza cover plan
live per neurocrin show broad payer coverag therefor posit outlook
ingrezza remain unchang despit announc assum us sale
compani indic plan commerci ingrezza outsid
unit state compani believ achiev level
reimburs need justifi ou commerci invest
believ ingrezza reach sale despit strong launch
base discuss physician market research believ
addit upsid base
ingrezza best-in-class treatment td due chiefli conveni dose per
discuss neurologist psychiatrist
continu commerci invest neurocrin maxim penetr
tardiv dyskinesia overview ingrezza best-in-class treatment option
tardiv dyskinesia td involuntari movement disord typic caus
chronic prolong first fga second gener antipsychot use commonli
bipolar schizophrenia depress note antiemet dopamine-block
drug metoclopramid prochlorperazin also caus td antipsychot
work mainli block postsynapt brain dopamin receptor affect
extrapyramid system ep motor system network brain nigrostriat pathway
respons involuntari action like restless akathisia rigid tremor slow
movement bradykinesia sga consid less ep side effect
multi-mechanist approach bind serotonin receptor addit receptor
time frame symptom appear differenti ep td symptom ep
symptom usual appear acut start therapi month resolv upon
cessat drug td symptom appear much later month continu
one month follow remov offend drug
pathophysiolog td unknown evid suggest medic
upregul postsynapt da receptor result increas dopamin signal
receptor hypersensit involuntari movement face arm hand feet leg trunk
stereotyp behavior tic rare tremor td irrevers occasion
lifelong result neg impact psycholog behavior physic disfigur
jerk
prior ingrezza approv limit treatment option td first line
approach treat td includ reduc dose discontinu dopamin block
medic switch fga efficaci first approach
well studi also mani patient taken dose reduc due debilit
natur underli condit schizophrenia bipolar disord second
approach fga shown efficaci current literatur inconsist
conflict clozapin prefer approach requir
frequent blood test monitor agranulocytosisa rare seriou condit
result low white blood cell level pharmacolog treatment td includ
benzodiazepin clonazepam botulinum toxin limit data mix
result efficaci short term backdrop evid
point inhibitor first line pharmacolog treatment research
suggest ingrezza austedo best option treatment td
ingrezza novel mechan highli support usag td continu
uptak among patient believ biolog clear inhibitor treat
td associ high level dopamin nigrostriat pathway
brain membran protein transport neurotransmitt dopamin
norepinephrin serotonin histamin cellular cytosol synapt vesicl
presynapt vesicl releas synapt cleft neuron thu increas
dopamin level caus side effect inhibit pathway less dopamin
avail synapt cleft caus td addit bind site greater
affin dopamin block greater percentag dopamin
compar neurotransmitt reduc neg effect
specif mechan import inhibitor block specif singl
step pathway directli respons lower dopamin level
comparison sga typic multipl bind site differ receptor specif
bind predict efficaci side effect profil opinion clear
advantag sga pharmacolog treatment
clinic trial evid highli support ingrezza td pivot trial
random double-blind placebo control trial ingrezza patient
moder sever td includ patient underli schizophrenia
schizoaffect disord mood disord figur primari endpoint
chang baselin use abnorm involuntari movement scale aim aim
scale item assess sever base clinic observ aim
current best tool assess td sever base channel check neurologist
psychiatrist studi display statist signific chang baselin
aim score mg/day ingrezza group
dose titrat ingrezza austedo
least squar mean chang
baselin aim
chang
aim score
chang
aim score
ingrezza austedo similar clinic efficaci key differenti focu
safeti profil dose titrat look pivot trial data believ
littl differ efficaci ingrezza austedo figur inde studi
met primari endpoint chang aim score baselin statist
signific vs placebo least squar mean chang baselin aim score
ingrezza compar austedo effect mean trial
produc similar efficaci note subtract placebo least squar
mean chang baselin differ greater ingrezza vs view
greater spread favor ingrezza without direct comparison difficult make
definit conclus channel check physician show see austedo
ingrezza similar efficaci assum efficaci similar key differenti
factor ingrezza simplifi daili dose requir complic
titrat period efficaci point view produc clinic benefit
patient tdbut review side-effect profil dose regimen
superior ingrezza
side-effect profil rel similar austedo black-box warn
suicid ideat overal believ nomin differ side effect
drug caus increas qt interv heart electr
cycl caus cardiac problem see figur detail side effect profil
pivot trial ingrezza austedo howev concern
regard black box warn austedo depress suicid ideat see
figur note warn appli patient huntington diseas
entir market td patientsbut could still concern psychiatrist
manag complex psychiatr condit td view lack
black box warn ingrezza pi reassur prescrib
lack dose titrat key differenti ingrezza austedo
believ once-daili dose ingrezza biggest competit advantag
austedo underestim commerci driver austedo requir
complic dose-escal titrat first week follow multipl daili dose
thereaft see figur patient miss dose must start titrat
convers ingrezza titrat period dose once-a-day
speak treat physician simpl dose import complianc particularli
td popul complianc alreadi difficult td patient like alreadi
multipl therapi underli psychiatr ill view greater conveni
dose could lead greater complianc could translat better real-world
outcom patient also suggest higher penetr among elig patient
support posit view ingrezza market
inde channel check neurologist psychiatrist display signific
prefer ingrezza simpl dose physician suggest ingrezza improv
complianc expect higher level patient complianc drive
increas sale higher share price
recent prescrib trend continu favor ingrezza support thesi total
prescript volum ingrezza significantli outpac austedo sinc initi
approv drug figur note estim austedo includ
huntington tdwith like scrip written former take
account despit potenti variabl data accuraci iqvia number
believ script number continu support view ingrezza remain
leader td think histor volum point prefer ingrezza
expect continu take larger share market long term
written ingrezza prescript dispens given posit
signal believ ingrezza could see strong increas new prescript nrx
due increas commerci effort under-penetrated market expect
smaller share switch sinc ingrezza alreadi command greater
share vs austedo
figur total prescript product sinc launch
ingrezza trx provid neurocrin austedo trx provid iqvia smart
model ingrezza td view td market
elig patient popul base age-adjust preval patient
prescrib antipsychot arriv million patient us key market
ingrezza assum market actual experienc symptom td
base studi carbon et al estim patient experi moder
sever td use patient estim dhir et al assum patient
actual treat like conserv could potenti increas leav
around patient actual treat preval number weight toward
charl martineau pm univers toronto figur ingrezza td market model
patient million unless note
popul take antipsychot medic gener
preval td
preval td
preval td
patient experienc td take antipsychot
patient moderate/sever td diagnos symptomat
patient tardiv dyskinesia treat
older patient greater percent patient experienc td older popul
commonli experi td highest risk exposur first
gener antipsychot newli diagnos patient typic younger prescrib
second gener antipsychot less commonli caus td
long-term commerci success stem neurocrin abil improv diagnosi
treatment number increas market share expect neurocrin increas
market share austedo becom wide view best-in-class therapi
project market share view neurocrin like make
largest gain increas diagnosi ultim treatment rate potenti
increas treatment diagnosi rate could independ contribut cumul revenu
final year exclus base conserv assess patent
potenti extens gain older popul newli diagnos
patient base analysi increas diagnosi treatment rate
would add potenti revenu els held constant figur
ingrezza td build
ingrezza patient round
gross net discount
us sale ingrezza tardiv dyskinesia million
price access reimburs assumpt decemb
wholesal acquisit cost wac price per bottl monthli
suppli thirti mg tablet assum medic taken month
arriv annual gross cost model conserv estim
gross-to-net discount base knowledg compar drug
complianc gross-to-net like vari quarter first quarter impact
insur reset medicar part donut hole like increas time
contract come play over-estim impact conserv
take account gross-to-net discount complianc rate
averag net revenu per patient prescrib ingrezza one year
compar estim per year wac austedo price
tablet bottl pill assum patient take
mg per day requir bottl annual recal dose titrat
rang per day
patient access ingrezza high contribut strong commerci launch much
initi commerci success driven high-unmet need efficaci patient
assist provid compani notabl neurocrin report patient
pay less prescript patient access
gener posit compani also report live cover
insur ingrezza addit channel check physician found
gener difficult get ingrezza coverag approv typic prior-author
form ingrezza rel easi physician character minim
push-back payer still compani provid much detail contract
payer state continu evalu case-by-cas basi
impact compani effort gain greater market share neurocrin focus mainli
greater penetr access patient pool compani initi improv
diagnosi treatment rate includ increas sale forc
new rep hire might transit period believ
increas invest sale forc good lead indic futur
trajectori ingrezza also suggest compani take conserv approach
sg spendonli increas sale forc warrant gener expect
increas sale team impact revenu closer larger workforc
field help expand health care provid network increas sg would
expect compani increas commerci effort
recognit td compani indic physician name psychiatrist
gener poor diagnos td sentiment corrobor discuss
psychiatrist neurologist anyth neurologist perceiv compani
like diagnos td train recogn movement disord
neurologist spoke agre state typic refer patient
primari care physician specif movement disord therefor
prime diagnos td hand psychiatrist thought diagnos td less
like ingrezza treatment td henc less incent
psychiatrist recogn condit gener train resid fellowship
also includ much content diagnos movement disord howev
treatment option exist believ psychiatrist make concert effort
recogn treat td
neurocrin previous suggest prescrib base approxim
percent split psychiatrist neurologist believ target physician
market mainli psychiatrist sinc condit like schizophrenia bipolar disord
mood disord typic first seen potenti opportun larger
neurocrin impact increas sale given psychiatrist encompass
major prescrib gener underdiagnos patient
compani launch unbrand direct-to-consum campaign call
talk td figur campaign televis online-bas program
focus diseas educ recognit earli effort impact
remain seen
focus physician educ
ip protect market exclus like current ip protect us
last extens current key composit matter patent expir
assum brand price exclus base provis
hatch-waxman act give neurocrin ten year brand name exclus
entri gener competitor figur detail key patent ingrezza
compani plan commerci ingrezza outsid us thu patent
europ materi compani current
composit matter
composit matter
overal think ingrezza best-in-class profil continu allow
neurocrin remain domin player td space ingrezza tourett
syndrom unsuccess believ current consensu expect like
conserv view ingrezza continu grow drive neurocrin revenu
base support dcf valuat discuss commercial-stag
asset neurocrin portfolio orilissa next section
orilissa endometriosi second commerci asset
second key asset neurocrin commercial-stag portfolio orilissa
gonadotropin-releas hormon antagonist approv treatment
moderate-to-sever pain associ endometriosi juli approv pi
neurocrin develop partner respons market sell
drug neurocrin entitl royalti mileston payment first fda-
approv oral medic treat endometriosi pain ten year drug
discov develop neurocrin complet phase ii studi
respons manufactur commerci orilissa neurocrin
receiv quarterli sale-bas royalti estim percentag
abbvi net sale addit neurocrin receiv mileston nda
submiss drug approv assum us sale orilissa
neurocrin partner indic believ achiev
requir level reimburs justifi ou commerci invest
revenu impact great ingrezza believ orilissa
potenti drive revenu growth via royalti approv
endometriosi indic potenti uterin fibroid indic approv
end-us sale estim in-lin consensu expect see figur abbvi
guid orilissa sale compani report sale
track meet estim like competit think
 neurocrin first-mov advantag critic primary-car market
orilissa key debat usag second-lin endometriosi earli
launch one key investor debat orilissa drug becom
second-lin treatment choic moder sever endometriosi fare
vs emerg competit gnrh space market model assum first-
line therapi remain nsaid combin oral contracept ocp due low cost
long-term experi support physician check moderate-to-
sever endometriosi typic stronger medic requir
altern orilissa efficaci less expens
signific side effect name lupron depot also sever competitor
class could erod market share approv think orilissa well
intercours dyspareunia
posit vs threat safeti profil orilissa much better
vs lupron use long-term first-mov advantag key
establish strong foothold market vs competitor class
orilissa requir add-back therapi myovant relugolix could
endometriosi overview approach treatment
endometriosi diseas overview endometrium innermost layer uteru
function prepar uteru potenti embryo implant menstrual
cycl cycl endometrium thicken vascular glandular tissu produc
optim environ embryo implant blood vessel gland continu
grow fertil embryo implant uteru eventu vasculatur fuse
form placenta provid nutrient oxygen develop fetu
embryo implant endometrium shed line hormon feedback
endometriosi common nonmalign process endometri gland
stroma deposit outsid uteru ectop deposit tissu outsid
uteru result local inflamm inflamm may caus chronic pain menstrual
symptom wide rang mild sever debilit common ectop
locat pelvi deposit also found bowel diaphragm pleural
caviti lung diseas estrogen-depend prolifer
endometrium larg depend circul level estrogen high level estrogen
earli menstrual cycl stimul endometri gland insid outsid uterin
caviti result characterist cyclic inflamm result pain common
endometriosi
pathogenesi endometriosi multifactori caus includ ectop
endometri tissu chang immun dysregul cell prolifer apoptosi
program cell death alter hormon signal genet factor endometriosi
affect women premenarch reproduct postmenopaus hormon stage
although reproduct period common women expos higher level
and/or longer period estrogen higher risk endometriosi use oral
hormon contracept pregnanc late menarch earli menopaus decreas
risk endometriosi lower estrogen exposur
hormon control therapeut option em endometri prolifer mainli
control estrogen menstrual cycl divid follicular luteal
phase follicular phase start onset mens end
lutein hormon surg earli follicular phase low circul level
estrogen progesteron caus hypothalamu brain releas gonadotropin-
follicl stimul hormon fsh lutein hormon lh pituitari gland
increas fsh stimul ovarian follicl growth process ovarian
follicl stimul result increas estrogen product ovari increas
estrogen product main catalyst rapid endometri develop thicken
next day endometrium grow accommod potenti
embryo higher circul estrogen level caus hypothalamu decreas gnrh
product ultim lower fsh approxim one day ovul
increas lh caus oocyt releas ovari lh surg start
approxim luteal phase result either pregnanc mens
fertil cycl relev understand current therapi treat
endometriosi specif target
drug target current therapi first-lin treatment endometriosi
combin nonsteroid anti-inflammatori drug nsaid oral contracept
ocp nsaid chosen cost access nsaid
shown superior agent accord recent cochran review compar
nsaid use manag pain em vs placebo addit nsaid
recommend long-term common side effect like stomach ulcer
believ ocp better longer term option first-lin treatment
gener well toler cheap provid contracept lower risk ovarian
endometri cancer ocp function prevent ovul suppress releas
gnrh drug contain synthet progesteron sometim estrogen
downregul puls frequenc gnrh releas hypothalamu slow fsh
lh product decreas ovarian follicl develop ultim lower
estrogen product lower circul level estrogen mean less endometri gland
growth uterin ectop subsequ less pain patient nsaid
and/or ocp control symptom wish becom pregnant treatment
cochran review report gnrh agonist leuprolid nafarelin provid
efficaci placebo differ compar levonorgestrel ocp
drug bind directli gnrh receptor pituitari gland gnrh agonist longer
half-lif increas time receptor occup elimin physiolog
pulsatil stimulu hypothalamic-pituitary-ovarian hpo axi need
proper function constant bind stimul fsh lh product increas
estrogen level approxim period high circul level estrogen
caus neg feedback gnrh product hypothalamu prolong
activ gnrh receptor gnrh lead desensit eventu suppress
gnrh secret seriou side effect result uncharacterist high level
tender bloat neg side effect see lupron depot month im
inject pi poor-sid effect profil leuprolid acet depot lupron depot make
drug short-term option accord physician spoke
gnrh antagonist like orilissa contrastingli compet gnrh pituitari receptor
bound receptor gnrh antagonist inhibit gnrh signal prevent
fsh lh product mechan result immedi effect unlik gnrh
agonist take day gnrh suppress gnrh antagonist also
avoid initi hormon flare associ gnrh agonist agonist effect
pituitari receptor gnrh agonist upregul hpo axi rather block initi
step gnrh antagonist
gnrh agonist antagonist caus seriou side effect relat low
circul level estrogen hypoestrogen side effect includ bone loss hot flash
vagin dryness mood swing headach add-back hormon therapi typic
given gnrh agonist fda recommend norethindron daili first line
therapi report advantag gnrh antagonist avoid add-back
therapi em treatment pivot trial orilissa use add-back therapi
mg dose show signific problem bone loss safeti issu higher
dose increas frequenc typic requir add-back therapi seen
dose elagolix prescrib twice daili gnrh antagonist clinic develop
also use add-back therapi higher dose long-term data head-to-head
comparison gnrh agonist antagonist need view figur
detail variou option treat endometriosis-rel pain
charl martineau pm univers toronto figur treatment option endometriosi
efficaci
decreas risk cancer
differ
differ
add-back therapi
unsuit patient seek pregnanc
orilissa commerci consider endometriosi
competit landscap believ orilissa posit potenti second-
line treatment choic em unlik would displac ocp first-lin therapi
due low cost efficaci long-term experi danazol anoth drug approv
endometriosi synthet steroid suppress hpo axi believ
third-lin choic due wide rang neg side effect associ long-term
steroid use therefor feel orilissa competit mainli gnrh agonist
lupron gnrh antagonist relugolix linzagolix
lupron leuprolid acet commonli use gnrh agonist drug
avail sinc avail gener form initi recommend
start mg inject depot formul maximum month price
around lupron shown similar efficaci ocp long-term
experi lupron may give slight advantag orilissa usag comfort
think side-effect profil neg differenti hormon surg caus
gnrh agonist signific disadvantag could potenti medic switch
hypoestrogen side effect anoth disadvantag although symptom
reason control estrogen-progestin add-back therapi patient usual need
take lupron long-term sinc associ relaps rate within
month drug cessat note usual option given poor side
synarel nafarelin acet anoth gnrh agonist produc
approv em administ nasal typic mcg twice daili
maximum month ml bottl cost typic last around day
therebi cost close month cours drug gener shown
similar efficaci lupron allevi em addit manuscript agarw et al
compar leuprolid vs nafarelin em suggest synarel associ lower
bone mass densiti loss less hot flash
regard rout administr prefer oral versu depot inject
debat gynecologist indic prefer depot formul
help complianc agre conveni associ singl dose
everi month compar daili medic requir visit physician
offic addit patient advers inject may prefer oral medic
believ major women prefer oral medic depot formul
use current contracept use benchmark nation health statist report
current contracept use us report women take oral
contracept compar inject depot-provera us women age
year therefor oral administr anoth driver favor orilissa
potenti prefer second-lin therapi evid exist
competit gnrh antagonist classcompetit data expect near-term
relugolix em switch gnrh antagonist class orilissa first fda
approv drug treat em first market class import sinc
drug greater penetr competitor entri sever compani gnrh
antagonist product relugolix myovant current enrol patient em
phase trial spirit top-line data data liberti trial
expect liberti trial could lead launch
uf launch em earliest note relugolix like co-
formul add-back hormon therapi single-tablet may
posit impact bmd hot-flash think physician prefer control use
oral contracept especi patient take anoth competitor
linzagolix obseva yet start phase trial endometriosi howev data
uf trial primros expect primros
figur figur detail up-to-d clinic data includ trial
design variou gnrh antagonist endometriosi
figur trial design profil gnrh antagonist
mg daili
daili
daili
chang baselin
menstrual non-
menstrual pain
chang baselin
pelvic pain week
respond week
month
month
month
chang bone
month
arm
efficaci profil rel similar across gnrh antagonist note
difficult compar apples-to-appl direct comparison
perform addit myovant use differ respond scale less data
avail phase trial despit drawback make infer use
chang bone miner densiti among three competitor three drug
dose-depend reduct bone miner densiti relugolix far largest
reduct like robust respons reason patient
phase treat add-back therapi elagolix linzagolix option
use add-back therapi base dose strength drug potenti take
signific market share feel market larg enough support three player
superior market formulari access prefer for/against add-back therapi
ultim drive brand prefer
orilissa market opportun endometriosi
elig popul estim potenti patient popul figur orilissa
patient symptomat us women reproduct age
year assum popul actual treat estim
treatabl patient elig orilissa accord recent earn slide
compani estim total address popul greater competit reduc
market share potenti relugolix linzagolix commerci earli
assum royalti sale neurocrin could see late-
em indic
figur orilissa market model us endometriosi
patient million unless note
women endometriosi diagnos symptomat
women endometriosi treat
orilissa patient round
gross net
us end-us sale million
royalti
us royalti revenu endometriosi million
price durat therapi em patient orilissa dose orilissa
base sever symptom patient start mg daili mouth
maximum therapi month patient experienc pain intercours dyspareunia
symptom control lower dose prescrib mg daili
maximum month monthli wac either mg mg regimen
approxim figur price regardless one two pill
taken daili wac mg regimen base month therapi
mg regimen annual
calcul weight annual wac orilissa endometriosi figur
assum conserv assum patient take higher dose therapi
dyspareunia month weight accord uptod link
preval dyspareunia conserv assum higher
preval rate sinc result lower annual weight cost convers assum
remain patient take mg daili regimen
month weight
expect patient take mg regimen dyspareunia pain intercours
take therapi maximum month assum patient take low dose
regimen mg daili maximum year continu therapi month
em commonli reoccur end therapi therefor assum patient take
orilissa maximum length month year long side effect
averag net annual price per endometriosi patient approxim
calcul blend wac assum gross-to-net discount
complianc
price monthli packag
mg daili annual length therapi month
patient mg regimen
mg daili annual length therapi month
patient mg regimen
exclus orilissa like least current ip protect elagolix last
approxim see figur model hatch-waxman brand
exclus patent held provid brand name price
exclus least year prior entri gener competitor expect
signific declin market penetr price patent expir orilissa
fda orang book follow patent link
elagolix uterin fibroid increment opportun
like launch
second opportun elagolix uterin fibroid potenti launch
like smaller revenu opportun think increment boost
uterin fibroid could drive end-us orilissa elagolix sale follow
posit phase data expect partner abl file snda
supplement new drug applic fda set potenti
approv similar time potenti launch relugolix uf
view opportun uf smaller endometriosi em partli due
market size symptomat us women em vs uf addit
surgic intervent provid definit treatment like continu
standard care contrast em surgeri less benefici inde patient
like treat elagolix month precursor surgeri suggest
physician check
despit believ smaller uf market larg unmet need still exist
safe efficaci treatment exist manag uf importantli elagolix potenti
first novel pharmacolog uf treatment year due proven efficaci
better side effect profil greater conveni given unmet need support
clinic data believ orilissa like commerci success figur
end user sale forecast uterin fibroid
figur elagolix project end-us sale unadjust uf
uterin fibroid overview uterin fibroid uf leiomyoma common
pelvic tumor women nearli half women fibroid age one
common indic hysterectomi us uf aris smooth muscl cell
uteru myometrium gener benign tumor grow uteru
becom cancer leiomyosarcoma case uf pathogenesi thought
result somat mutat dna alter occur birth muscl cell
myocyt somat mutat differ germlin mutat
pass offspr studi suggest potenti genet compon therefor
exact caus elucid
major women uf asymptomat howev
symptomat disrupt normal life women symptom vari
patient occur differ size number locat
uteru women commonli experi abnorm uterin bleed
abdomin cramp relat tumor mass-effect uf also caus bladder bowel
dysfunct reproduct problem like infertil symptom commonli present
third fourth decad life black women increas incid
exhibit symptom year earlier white women predispos factor
includ exposur estrogen progesteron includ nullipar never
given birth earli onset mens clinic diagnosi usual confirm
ultrasound histolog confirm necessari sinc uf rare malign
review current therapeut option uf figur highlight symptomat
need treat surgeri remov
figur current therapeut standard uterin fibroid
risk fibroid
improv bleed
amenorrhea
may
volum
safeti
greater se
ocp gener
moder efficaci
use mani
intens
greater se
ocp
efficaci
use mani
decreas
associ
surgeri larg consid definit treatment uf elagolix would like
use prior reduc tumor burden symptom sever surgic
procedur myomectomi endometri ablat use uf although hysterectomi
common hysterectomi stop symptom prevent
reoccurr sinc tumor remov also provid protect
gynecolog cancer cervic endometri uterin surgic intervent less suit
women multipl comorbid would increas risk associ surgeri
medic therapi becom attract option case addit women
child-bear age may wish delay hysterectomi childbirth
medic therapi remain first-lin treatment despit surgeri definit
treatment conserv approach commonli first step sever option exist
treat symptom uf although clinic evid rel thin inconsist
accord viswanathan et al like owe success surgeri ocp
estrogen-progestin contracept help endometriosi limit efficaci
uf may help decreas uterin bleed typic help bulk
symptom pain pressur tumor data conflict among studi
actual suggest ocp contraind
uf progestin-onli contracept
levonorgestrel-releas intrauterin system progestin implant inconsist
data consensu regard use exist progesteron receptor modul
use first-lin therapi countri fda approv us concern
exist long-term could increas risk endometri cancer
gonadotropin-releas hormon gnrh agonist first-lin medic therapi
us discuss moa gnrh agonist note gnrh antagonist
current approv treatment uf elagolix could one first
main advantag gnrh antagonist conveni associ oral dose
avoid hormon surg initi titrat stronger dose requir uf
vs em achiev efficaci necessit co-administr add-back hormon
therapi avoid hypoestrogen side effect bone loss
discuss moa elagolix endometriosi section highlight clinic data
phase program figur view data support
approv snda expect file set mid-
figur clinic trial elagolix uterin fibroid
volum month
reduct
volum month
reduct
two random double-blind studi elaris-i/ii compar placebo
mg elagolix plu hormon add-back therapi month trial met primari
secondari endpoint month trial show signific reduct
menstrual blood loss month elaris-i popul cohort continu
extens studi elaris-extend
phase trial relugolix met primari endpoint key secondari
endpoint miss reduct uterin fibroid volum liberti
trial gener posit think miss secondari endpoint reduct
uterin fibroid volum could impact potenti commerci note despit
use add-back therapi combin relugolix reduct bone
miner densiti bmd spine vs placebo vs week
expect similar data liberti trial think data like suffici
fda approv believ
commerci drug slide myovant
elagolix market opportun uterin fibroid
feel elagolix could potenti first-lin medic therapi given good
efficaci side-effect profil patient uf peak sale
royalti expect drug overtak surgeri surgeri
provid definit treatment potenti cur elagolix aim
symptom control elagolix non-cur current medic therapi either
lack efficaci caus signific side effect view uf market wide
open new therapi take pharmacolog space note competit
expect gnrh antagonist direct threat come relugolix
myovant could difficult
highlight market like larg enough support therapi
model high penetr elagolix address patient
potenti em indic relugolix co-formul add-back hormon therapi
could deterr physician
forecast uf end-us sale potenti peak sale
assum royalti could gener increment royalti
neurocrin uf market like smaller term end-us sale continu
believ opportun could provid addit upsid neurocrin revenu
compani report suggest women uf us assum
patient treat elagolix uf treat maximum six month
adjunct treatment prior surgeri could see addit upsid number
patient orilissa remain therapi longer month averag
model assumpt elagolix uf assum launch elagolix
follow plan snda submiss uf price
perspect assum monthli wac em indic
howev given believ mani patient ultim elect surgeri
think averag durat therapi less em forecast approxim
month per patient gross wac per patient per year approxim
monthli packag price month treatment see figur detail assum
modest annual price increas gross-to-net discount complianc
gross annual revenu per patient
figur elagolix uf price assumpt
price monthli packag wac
annual length therapi month
market model assum women uf approxim
diagnos symptom warrant some-sort treatment
patient assum treat sort therapeut agent like prior
surgeri seen cur give us base patient popul
approxim patient could elig orilissa assum
modest penetr stare increas long-term product gain
commerci traction expect portion hysterectomi patient
treat elagolix assum neurocrin receiv royalti initi
increas per discuss compani royalti structur
peak end-us sale reach royalti neurocrin reach
figur market model em assum exclus
expect signific drop sale overal believ elagolix
signific player uf space expect smaller intrins valu
compar use em market current dcf valuat base uf case
charl martineau pm univers toronto figur elagolix uf market model us
patient million unless note
women uterin fibroid
women uterin fibroid diagnos symptomat
women uterin fibroid treat
orilissa patient round
gross net
us end-us sale million
royalti
us royalti revenu uterin fibroid million
parkinson diseas
acquisit modest revenu opportun
neurocrin acquir us right bial opicapon treatment parkinson
diseas believ asset nice tuck current neurolog focu
compani licens deal announc earli opportun modest
vs ingrezza peak sale think requir invest minim win
fda approv well worth initi invest addit
potenti mileston highlight neurocrin run addit
phase trial seek fda approv contribut posit npv
deal per origin deal neurocrin pay bial percentag net sale exchang
manufactur suppli drug product essenti cost product manufactur
royalti estim analysi expect neurocrin submit nda
fda potenti approv commerci launch us
earli note drug alreadi approv europ
commerci bial dcf valuat neurocrin assum
opicapon contribut close
opicapon comt inhibitor
opicapon background opicapon brand name europ ongenti develop
bial privat compani europ approv european regul
bipark-ii februari neurocrin obtain exclus licens right
develop commerci opicapon us canada receiv
guidanc fda neurocrin plan use pivot bipark-i/ii trial data
nda submiss expect figur
chang off-tim
compani data link clinic trial
bipark-i result show statist signific reduct off-tim use
mg opicapon dose compar placebo minut compar entacapon
show minut reduct off-tim compar placebo result show
opicapon extend levodopa hour entacapon appear less
off-tim minut
compani data link clinic trial
bipark-ii trial confirm efficaci opicapon mg dose cohort
result statist signific chang off-tim compar placebo
minut mg cohort show statist signific evid compar
placebo pivot trial provid evid opicapon levodopa extend
opicapon show evid fulmin hepat associ tolcapon
common side effect includ dyskinesia constip increas blood
opicapon versu comt inhibitor opicapon potenti best-in-
class due proven efficaci better profil simplifi dose competitor
believ main competitor entacapon still approv us feel
tolcapon pose small competit risk due associ toxic black box
warn liver failur link pi pivot clinic trial bial provid posit
evid drug bipark-i suggest potenti greater therapeut effect
compar entacapon reduc off-tim studi show opicapon
reason toler patient addit opicapon competit edg
simplifi once-daili dose entacapon given time daili dose
pharmacolog burden pd patient opicapon rel late market better
side effect profil efficaci conveni may prove anoth me-too
market opportun estim patient us pd market pd
drug estim compound-annual-growth-rate
accord report transpar market research link report howev
space crowd number differ class within class host
competitor exist believ potenti opportun opicapon somewhat
protect versu pd class reli co-administr levodopa
larg recogn effect therapi prior bipark-i/ii trial would
given less credit comt inhibitor class base modest efficaci
signific side effect opicapon help reviv drug class meaning efficaci
better side effect profil greater conveni
increas complianc
patient million unless note
adult pd
new case annual pd
total adult pd
adult take levodopa carbidopa pd
opicapon patient round
gross net
us unadjust sale opicapon million
base expect nda file project potenti launch see
figur sale potenti peak prior loe
assum around year exclus assum annual wac price around
per discuss compani gross-to-net discount
complianc averag gross annual cost per patient project modest
market penetr peak opicapon due competit confus among
avail option plethora avail drug confound patient
physician may limit drug adopt market could see addit upsid
base neurocrin abil commerci market drug note around
two-third patient pd levodopa would target popul
market still significantli
under-penetrated base peak estim therefor improv effort regard
physician patient educ could provid meaning growth believ consensu
expect conserv see figur forecast vs consensu
leav signific portion
parkinson diseas overview approach treatment
diseas overview parkinson diseas pd chronic progress neurolog
disord commonli due degen loss dopaminerg neuron brain
typic present slow movement bradykinesia rest tremor bodi rigid
postur instabl precis caus pd unknown prevent treatment
exist etiolog presum multifactori complex mechan neuron
degener includ protein misfold mitochondri dysfunct oxid stress
among other mani case thought sporad strong genet compon
associ pd younger patient year accord singelton et al pd
sever limit lifestyl may eventu result death cdc link
statist rate complic pd caus death us addit
pd second common neurodegen diseas alzheim diseas
us
current treatment option pd host pharmacolog treatment option exist
pd rang efficaci side effect figur levodopa gener believ
effect treatment symptomat pd levodopa dopamin precursor
improv symptom replac dopamin brain lost degener
dopamine-produc neuron substantia nigra drug activ insid central
nervou system within blood-brain barrier typic combin
carbidopa peripher decarboxylas inhibitor vehicl deliv activ drug
gut bloodstream carbidopa help prevent breakdown levodopa outsid
blood-brain barrier reduc neg side effect import drawback
wearing-off
phenomenon physician mitig motor fluctuat use lower dose
increas dose interv reduc total number dose focu find
balanc levodopa use control symptom avoid wearing-off
fluctuat known
charl martineau pm univers toronto figur fda approv treatment pd
levodopa
dopamin
treatment
ineffect
monotherapi
combo
use
patient
use
use young
increas risk
modest benefit
contraind
older dement
comt catechol-o-methyl transferas inhibitor use help extend effect
levodopa attempt prevent levodopa breakdown permit use
lower levodopa dose extend period drug effect drug effect
increas time reduc time unfortun medic class
shown mix efficaci signific side effect accord stride-pd trial
stocchi et al entacapon combin levodopa show efficaci delay
time onset reduc dyskinesia compar levodopa alon addit anoth
comt inhibitor tolcapon associ hepatotox fulmin hepat
subsequ remov eu canadian market three death
congenit adren hyperplasia posit
phase need clariti fda path
investig asset treat congenit adren hyperplasia
recent posit top-lin data phase proof concept trial give us
confid asset corticotropin-releas factor type
receptor antagonist could first non-steroid treatment diseas
essenti drug prevent excess product androgen without need
corticosteroidsreduc potenti impact long-term steroid usag
improv underli diseas eventu approv could see peak sale
assum orphan price rel high penetr elig patient
phase top line data suggest efficaci adult neurocrin meet
fda determin path forward registration-direct program adult
pediatr patient get mani specif top-lin releas
phase trial know demonstr reduct least percent
baselin adrenocorticotrop hormon acth
level percent patient treat day
observ meaning reduct biomark includ
androstenedion safeti profil also clean seriou
clinicaltri gov entri trial found
believ primari opportun children given sever
classic form potenti impact growth develop could see
addit upsid compani activ pursu adult indic inde compani
emphas focu treat patient earli life possibl
diseas babi born genet lesion allow
updat program includ detail path forward pivot trial
could get closer end year estim compani also
indic pivot program could start adult later year pediatr like
follow
diseas overview congenit adren hyperplasia rare genet condit
patient adren gland malfunct caus autosom
recess inherit mutat gene result defici
hydroxylas enzym respons biochem regul mineralocorticoid
glucocorticoid steroidogenesi sex steroid produc adren gland
without hormon defici overproduct occur result
seriou life-threaten system effect includ atyp genitalia viril
mental dysfunct infertil adren crisi figur market model
current standard care steroid obviou long-term
consequ steroid cur treatment exist therefor see
signific opportun neurocrin market success pivot trial
current like risk/reward like limit valu program
pipelin inde current model modest po program base
posit top line phase poc-proof concept data approxim
dcf analysi share
us popul million
children
children diagnos symptomat
children treat
gross net
us unadjust sale million
collabor voyag therapeut neurolog
parkinson
neurocrin foray gene therapi recent sign collabor agreement
voyag therapeut januari neurocrin voyag enter
collabor agreement develop gene therapi potenti treat pd
friedreich ataxia fa neurocrin paid voyag up-front cash
equiti invest access vy-aadc pd fa think
anoth posit busi develop invest diversifi pipelin
still stay core neurolog focu seen littl data specif
gene therapi product asid phase trial publish annal
neurolog link deal repres lower-risk entri point gene therapi
program expect next key data point includ updat enrol
phase clinic trial pd first patient decemb updat
inform candid select program fa
deal specif asid up-front financi commit neurocrin
neurocrin respons fund clinic develop vy-aadc
complet phase trial voyag option co-
commerci asset neurocrin us cost profit share
arrang ou voyag would elig mileston royalti ou sale
voyag could also grant neurocrin full global commerci right exchang
mileston payment royalti
deal also call neurocrin fund develop
phase clinic trial similar pd program voyag option co-
commerci us cost profit split voyag could also
grant neurocrin full ww commerci right exchang mileston payment
royalti base global sale sanofi option commerci fa
program ou term also call neurocrin fund develop two addit
potenti mileston royalti rate
aadc program develop mileston
us royalti mid-teen thirti percentag net sale
ou royalti low-teen twenti percentag net sale
fa program develop mileston
us royalti low-teen high-teen percentag net sale
ou royalti high-singl digit mid-teen percentag net sale
addit discov program
us royalti high-singl digit mid-teen percentag net sale
ou royalti mid-singl digit low-teen percentag net sale
aggreg commerci mileston collabor product
total
vy-aadc detail initi clinic data potenti opportun goal gene
therapi restor aadc aromat l-amino acid decarboxylas enzym activ
improv levodopa sensit hope also improv clinic motor function pd
loss neuron critic aadc enzym midbrain produc dopamin
lead progress loss motor function less respons levodopa see
charl martineau pm univers toronto figur role aadc enzym pd
data phase trial suggest neural administ gene therapi
abil improv amount on-tim time patient experi
troublesom dyskinesia overal qualiti life figur figur key
earli clinic data appear support gene-therapi clinic benefit
patient diagnos year rel advanc diseas also
found shift diseas progress support indic might help
significantli slow diseas therapi address believ
toxic accumul alpha-synuclein like impact progress
physic symptom figur see drug compet anti-
alpha-synuclein approach rather like complimentari also signific
reduct levodopa-equival dose led notabl saw reduct led
cohort month reduct cohort year first cohort
increas led dose year due singl patient see figur
full detail phase trial found christin et al magnet
reson imaging-guid phase trial putamin aadc gene therapi parkinson
diseas annal neurolog
charl martineau pm univers toronto figur phase efficaci data vy-aadc pd patient cohort
figur chang time per
figur qualiti life improv
figur shift diseas progress
charl martineau pm univers toronto safeti yv-aadc look accept especi given sever diseas
patient invas therapi administr voyag note
follow regard safeti profil yv-aadc
surgic procedur success complet patient phase trial
patient discharg hospit within day follow surgeri
infus well toler vector-rel sae
one patient experi two saesa pulmonari embol relat heart
patient treat anti-coagul complet resolut
sae
determin sae caus immobl
surgic procedur dvt prophylaxi ad surgic protocol
follow event subsequ event observ
phase trial design trial random double-blind
placebo-control evalu efficaci vy-aadc patient trial
motor
clinicaltri gov entri found detail trial includ
medic manag
fluctuat
popul parkinson diagnosi year adequ respond
oral medic hour time
random design patient random either one-tim administr
vy-aadc total dose vector genom placebo
primari endpoint time without troublesom dyskinesia good time
measur self-report patient diari month endpoint
secondari endpoint diari time motor function qualiti life
patient global function measur
proport particip improv clinic global impress
score also includ non-motor symptom safeti
biomark data vy-aadc putamin coverag aadc enzym express
activ pet scan chang patient daili dose oral levodopa
current includ direct valuat vy-aadc program
includ assum return dcf given phase data
program comfort neurocrin invest pd program
fa opportun earlier lead candid select expect
note current avail treatment modifi diseas progress
accord neurocrin approxim patient us
experi symptom onset year life expect year
patient genet defect reduc product frataxin protein exact
role protein remain unclear thought help regul iron transfer
cell mitochondria without enough frataxin energi mitochondria aka cell
powerhous fall caus cell damag
program aim deliv function fxn gene restor frataxin level
least normal relev neuron cardiac myocyt voyager/neurocrin
use believ novel bbb penetr capsid optim deliveri
transduct system therapi therapi allow potenti administr affect
tissu heart progress phase clinic program support
pre-clin data knockout mous model diseas
forecast neurocrin incom statement balanc sheet statement
project fy revenu forecast
fy non-gaap ep figur incom
statement balanc sheet found figur statement cash flow
found figur
opicapon sale
product sale
revenu
revenu
revenu
profit loss tax
weight averag share basic million
weight average share use calcul dilut ep
cash equival
prepaid expens current asset
properti equip net
commit conting
accumul comprehens loss
figur neurocrin statement flow
depreci amort
chang asset liabil
account payabl accru liabil
net cash use oper activ
purchas properti equip capital-expenditure
sale properti equip
purchas invest
sale/matur invest
net cash use invest activ
issuanc common stock net
repay debt oblig
proce issuanc senior convert note net
net cash use financ activ
net decreas increas cash cash equival
cash equival begin period
adjust restrict cash
cash equival end period
cs peer relationship neurocrin
peer global databas captur uniqu inform compani within
credit suiss coverag univers base relationship compani
custom supplier competitor databas built research analyst
insight regard relationship credit suiss cover compani global
compani form core peer databas also includ relationship
stock coverag
figur cs peer relationship map neurocrin
author report evan seigerman would like acknowledg work
matthew terwelp md adrian garcia associ credit suiss larg cap
kevin gorman ph founder neurocrin start execut
vice presid chief busi offic senior vice presid busi
develop neurocrin bioscienc subsequ serv chief oper
offic prior work neurocrin princip avalon medic partner
respons earli stage found neurocrin sever
biotechnolog compani metra biosystem idun
receiv ph immunolog financ
univers california lo angel addit post-doctor train
matthew abernethi start career kpmg llp nearli year
experi healthcar industri mr abernethi previous zimmer biotmet
appoint neurocrin chief financi offic novemb
chain oper inform technolog investor relat function neurocrin
mr abernethi earn bachelor degre account busi administr
grace colleg univers chicago
eiri robert year experi pharmaceut industri
prior join neurocrin held posit compani includ vice
presid clinic pharmacolog vice presid biomedicin busi
addit chair medic review committe respons
review approv integr clinic plan molecul lilli portfolio
appoint chief medic offic januari respons
clinic develop medic affair activ neurocrin dr robert physician
train pharmacolog medicin uk qualifi univers
london post-gradu clinic train clinic pharmacolog
cardiolog st bartholomew hospit royal london hospit
dr bozigian particip around year prior neurocrin serv
director develop procyt corpor associ director
pharmacokinet drug metabol sphinx pharmaceut corpor
clinic pharmacokineticist glaxosmithklin appoint chief develop
offic decemb prior senior vice presid
preclin develop respons includ preclin develop
chemistri manufactur control clinic pharmacolog earn
 microbiolog univers massachusett pharmacodynam
toxicolog univers nebraska medic center earn ph
pharmaceut scienc univers arizona
dr grigoriadi start du pont pharmaceut compani
join neurocrin respons research activ neurocrin
special crf receptor antagonist develop author co-author
public neurosci neuropharmacolog field dr grigoriadi
receiv sc univers guelph ontario canada sc
ph pharmacolog univers toronto ontario canada conduct
postdoctor research nation institut drug abus baltimor
dr gano start neurocrin posit market analyt
busi develop respons busi corpor develop
activ neurocrin includ manag on-going collabor
bial mitsubishi tanab pharma sumitomo dainippon pharma receiv
chemistri univers oregon biochemistri univers
washington ph organ chemistri financ
univers california lo angel
malcolm lloyd-smith previous serv senior vice presid regulatori affair
depart prior held variou
offic posit appoint
chief regulatori offic septemb respons regulatori affair
qualiti assur mr lloyd-smith hold sc pharmacolog univers
leed sc pharmacolog biochemistri hatfield polytechn
mr lippoldt appoint chief legal offic neurocrin prior
execut vice presid gener counsel chief complianc offic volcano
corpor gener counsel
start corpor secur law law firm fulbright
 jaworski llp matthew branscomb mr lippoldt receiv
financ intern relat st mari univers
mr benevich year experi pharmaceut industri
posit peninsula pharmaceut astrazeneca immedi prior
neurocrin vice presid market avanir pharmaceut
appoint chief commerci offic may respons aspect
commerci develop market sale neurocrin product portfolio mr
benevich bba intern busi washington state univers
juli cook previous held senior posit sanford burnham prebi medic
research institut start career
human resourc hold bachelor art econom colorado
charl martineau pm univers toronto compani mention price
